2024
Public Health Impact of FDA’s Request for Additional Safety Data on Cytisine for Tobacco Cessation
Reddy K, Paltiel A, Freedberg K, Rigotti N. Public Health Impact of FDA’s Request for Additional Safety Data on Cytisine for Tobacco Cessation. JAMA Health Forum 2024, 5: e242647. PMID: 39177985, PMCID: PMC11344233, DOI: 10.1001/jamahealthforum.2024.2647.Peer-Reviewed Original ResearchConceptsPublic health benefitsCessation medicationsSmoking cessationStop smokingLife yearsLong-term abstinenceCivilian noninstitutionalized adultsTobacco cessation treatmentTobacco cessation medicationsPotential public health benefitsPopulation-level life expectancyLife expectancySmoking cessation medicationsLife expectancy gainsHealth benefitsPotential public health impactPublic health impactSmoking cessation aidTobacco cessationNoninstitutionalized adultsNoninstitutionalized populationMain OutcomesCessation treatmentCessation aidsYear of availabilityComparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States
Park H, Gonsalves G, Tan S, Kelly J, Rutherford G, Wachter R, Schechter R, Paltiel A, Lo N. Comparing frequency of booster vaccination to prevent severe COVID-19 by risk group in the United States. Nature Communications 2024, 15: 1883. PMID: 38448400, PMCID: PMC10917753, DOI: 10.1038/s41467-024-45549-9.Peer-Reviewed Original ResearchConceptsSevere COVID-19Risk of severe COVID-19COVID-19 booster vaccinationBooster vaccinationHigh-risk populationAbsolute annual riskWaning of protectionImmunocompromised populationsFrequent boostingOlder age groupsAnnual boosterImmune evasionImmunocompromised personsPublic health needsPublic health guidanceRisk groupsFrequent boostersImmune statusRisk factorsFrequency of booster vaccinationHealth needsHealth guidanceCompare frequenciesAge groupsVaccine
2022
Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States
Huizinga JL, Stanley EE, Sullivan JK, Song S, Hunter DJ, Paltiel AD, Neogi T, Edwards RR, Katz JN, Losina E. Societal Cost of Opioid Use in Symptomatic Knee Osteoarthritis Patients in the United States. Arthritis Care & Research 2022, 74: 1349-1358. PMID: 33629485, PMCID: PMC8382774, DOI: 10.1002/acr.24581.Peer-Reviewed Original ResearchConceptsSymptomatic knee osteoarthritisOpioid use disorderOpioid useMcMaster Universities Osteoarthritis Index (WOMAC) pain scoreSymptomatic knee osteoarthritis patientsLong-term pain managementProlonged opioid usePublic health causeStrong opioid useSocietal costsKnee osteoarthritis patientsSocietal economic burdenDirect medical costsMedicare Current Beneficiary SurveyOsteoarthritis Policy ModelCriminal justice costsOUD prevalencePain scoresSD ageOpioid regimensPain managementKnee osteoarthritisOsteoarthritis patientsWestern OntarioMedical costs
2021
The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis.
Chen AT, Bronsther CI, Stanley EE, Paltiel AD, Sullivan JK, Collins JE, Neogi T, Katz JN, Losina E. The Value of Total Knee Replacement in Patients With Knee Osteoarthritis and a Body Mass Index of 40 kg/m2 or Greater : A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2021, 174: 747-757. PMID: 33750190, PMCID: PMC8288249, DOI: 10.7326/m20-4722.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioBody mass indexTotal knee replacementKnee replacementCost-effectiveness analysisTKR recipientsKnee osteoarthritisMass indexEnd-stage knee osteoarthritisLong-term clinical benefitCost-effective strategyPreoperative pain levelNational InstituteOsteoarthritis Policy ModelLifetime medical costsCost-effectiveness ratioBase-case analysisProbabilistic sensitivity analysesMultiple comorbiditiesCost-effectiveness perspectivePain levelsComplication rateClinical benefitCardiovascular diseaseMedical costs
2020
Quality‐Adjusted Life‐Years Lost Due to Physical Inactivity in a US Population With Osteoarthritis
Losina E, Silva GS, Smith KC, Collins JE, Hunter DJ, Shrestha S, Messier SP, Yelin EH, Suter LG, Paltiel AD, Katz JN. Quality‐Adjusted Life‐Years Lost Due to Physical Inactivity in a US Population With Osteoarthritis. Arthritis Care & Research 2020, 72: 1349-1357. PMID: 31350803, PMCID: PMC6982563, DOI: 10.1002/acr.24035.Peer-Reviewed Original ResearchConceptsKnee osteoarthritisCases of cancerPhysical activityPhysical inactivityUS populationCardiovascular diseasePA levelsQuality-adjusted life year (QALY) lossBlack Hispanic womenHealth benefitsInsufficient physical activityQuality-adjusted life yearsLife-year lossHigher PA levelsRace/ethnicityDiabetes mellitusHispanic womenOsteoarthritisQALY lossLife yearsOsteoarthritis InitiativeLoss burdenDisease controlImproved healthActivity levelsNovel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population
Reddy KP, Bulteel AJB, Levy DE, Torola P, Hyle EP, Hou T, Osher B, Yu L, Shebl FM, Paltiel AD, Freedberg KA, Weinstein MC, Rigotti NA, Walensky RP. Novel microsimulation model of tobacco use behaviours and outcomes: calibration and validation in a US population. BMJ Open 2020, 10: e032579. PMID: 32404384, PMCID: PMC7228509, DOI: 10.1136/bmjopen-2019-032579.Peer-Reviewed Original ResearchConceptsNational Health Interview SurveyCessation ratesQuit attemptsTobacco useMortality riskSmoking relapseSurveillance Modeling Network (CISNET) modelsNational Death IndexHealth Interview SurveyCigarette smoking behaviorNicotine product useExternal validationCumulative mortality curvesTobacco control policiesTobacco use behaviorsCurrent smokersDeath IndexSmoking prevalenceSustained abstinenceUS womenRelapseSmoking behaviorWomen/menUS populationNatural history
2019
Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis
Losina E, Smith KC, Paltiel AD, Collins JE, Suter LG, Hunter DJ, Katz JN, Messier SP. Cost‐Effectiveness of Diet and Exercise for Overweight and Obese Patients With Knee Osteoarthritis. Arthritis Care & Research 2019, 71: 855-864. PMID: 30055077, PMCID: PMC6349519, DOI: 10.1002/acr.23716.Peer-Reviewed Original ResearchMeSH KeywordsAgedCaloric RestrictionComparative Effectiveness ResearchComputer SimulationCost-Benefit AnalysisExerciseFemaleHealth Care CostsHealthy LifestyleHumansMaleMiddle AgedModels, EconomicMonte Carlo MethodObesityOsteoarthritis, KneeQuality of LifeQuality-Adjusted Life YearsRisk Reduction BehaviorTime FactorsTreatment OutcomeWeight LossConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesKnee osteoarthritisObese patientsIntensive dietSocietal perspectiveHealth care sector perspectiveLifetime costsOsteoarthritis Policy ModelCost-effectiveness ratioIDEA trialPain reductionUsual careExercise programArthritis trialsTreatment strategiesLifetime horizonClinical practicePatientsOsteoarthritisOverweightQALYHealth care sectorWeight reductionDiet
2018
Cost-effectiveness of health coaching and financial incentives to promote physical activity after total knee replacement
Smith KC, Paltiel AD, Yang HY, Collins JE, Katz JN, Losina E. Cost-effectiveness of health coaching and financial incentives to promote physical activity after total knee replacement. Osteoarthritis And Cartilage 2018, 26: 1495-1505. PMID: 30092263, PMCID: PMC6202236, DOI: 10.1016/j.joca.2018.07.014.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioProbabilistic sensitivity analysesFinancial incentivesOne-way sensitivity analysesDeterministic sensitivity analysesCost-effectiveness ratioSensitivity analysisCost-effectiveness outcomesOsteoarthritis Policy ModelEfficacy of THCKnee replacement recipientsPolicy modelLife yearsTelephonic health coachingQALYHealthcare perspectiveCost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation
Losina E, Usiskin I, Smith S, Sullivan J, Smith K, Hunter D, Messier S, Paltiel A, Katz J. Cost-effectiveness of generic celecoxib in knee osteoarthritis for average-risk patients: a model-based evaluation. Osteoarthritis And Cartilage 2018, 26: 641-650. PMID: 29481917, PMCID: PMC6334297, DOI: 10.1016/j.joca.2018.02.898.Peer-Reviewed Original Research
2017
Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States
Reddy KP, Kong CY, Hyle EP, Baggett TP, Huang M, Parker RA, Paltiel AD, Losina E, Weinstein MC, Freedberg KA, Walensky RP. Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. JAMA Internal Medicine 2017, 177: 1613-1621. PMID: 28975270, PMCID: PMC5675744, DOI: 10.1001/jamainternmed.2017.4349.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusLung cancer mortalityAge 40 yearsAntiretroviral therapyLung cancerCancer mortalityLower lung cancer mortalityIncomplete ART adherenceLung cancer deathsAge 80 yearsRisk of deathMortality risk ratioHigher overall mortalityStandard demographic dataGreater AIDSLight smokersSmoking exposureCurrent smokersFormer smokersART adherenceModerate smokersOverall mortalitySmoking habitsSmoking statusImmunodeficiency virusCost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings
Antillón M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine 2017, 35: 3506-3514. PMID: 28527687, PMCID: PMC5462484, DOI: 10.1016/j.vaccine.2017.05.001.Peer-Reviewed Original ResearchConceptsRoutine infant vaccinationCost-effectiveness analysisOptimal strategyHealthcare payer perspectiveVaccine priceOne-time catchMiddle-income countriesIntervention costsPayer perspectiveInfant vaccinationDong ThapRoutine vaccinationMiddle-income settingsTyphoid transmissionRate of hospitalizationNumber of dosesDynamic modelPricesWorld Health OrganizationInvestmentLwakReturnWillingnessTyphoid feverVaccination
2016
Cost‐Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis
Smith SR, Katz JN, Collins JE, Solomon DH, Jordan JM, Suter LG, Yelin EH, Paltiel AD, Losina E. Cost‐Effectiveness of Tramadol and Oxycodone in the Treatment of Knee Osteoarthritis. Arthritis Care & Research 2016, 69: 234-242. PMID: 27111538, PMCID: PMC5378156, DOI: 10.1002/acr.22916.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioQuality-adjusted life yearsOA patientsTKA outcomesKnee OA patientsKnee osteoarthritis treatmentInfluence of opioidsOsteoarthritis Policy ModelCost-effectiveness ratioConservative treatmentPain reductionPain reliefPersistent painKnee osteoarthritisMean ageTKA utilizationTreatment optionsOsteoarthritis treatmentLife yearsOxycodoneTramadolTKALifetime costsOpioidsOutcomesImpact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study
Reddy KP, Parker RA, Losina E, Baggett TP, Paltiel AD, Rigotti NA, Weinstein MC, Freedberg KA, Walensky RP. Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study. The Journal Of Infectious Diseases 2016, 214: 1672-1681. PMID: 27815384, PMCID: PMC5144729, DOI: 10.1093/infdis/jiw430.Peer-Reviewed Original ResearchConceptsSmoking statusSmoking cessationUS smokersLife expectancyT-cell countsHIV treatment programsAge 40 yearsYears of lifeSex-specific dataAntiretroviral therapyInitial CD4Current smokersFormer smokersHIV diseaseHIV infectionCigarette smokingMortality riskSmokersHIVSmoke cigarettesYounger ageTreatment programCessation ageSmokingCessation
2015
Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration
Losina E, Michl G, Collins JE, Hunter DJ, Jordan JM, Yelin E, Paltiel AD, Katz JN. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. Osteoarthritis And Cartilage 2015, 24: 776-785. PMID: 26746146, PMCID: PMC4838505, DOI: 10.1016/j.joca.2015.12.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAnti-Inflammatory Agents, Non-SteroidalCost-Benefit AnalysisDisease ProgressionDrug CostsFemaleHealth Care CostsHealth Services ResearchHumansInfusions, IntravenousInjections, SubcutaneousMaleMiddle AgedModels, EconometricNerve Growth FactorOsteoarthritis, KneePain MeasurementQuality-Adjusted Life YearsSelf AdministrationUnited StatesConceptsNerve growth factor inhibitorsQuality-adjusted life yearsStandard of careTotal knee replacement surgeryIncremental cost-effectiveness ratioGrowth factor inhibitorsKnee osteoarthritisFactor inhibitorsOA progressionSelf-administered subcutaneous injectionsSevere knee osteoarthritisDirect medical costsKnee replacement surgeryQuality-adjusted life expectancyOsteoarthritis Policy ModelCost-effectiveness ratioMeans of administrationBase-case analysisCost-effective treatmentHospital deliveryIntravenous infusionDisease progressionLifetime riskReplacement surgerySubcutaneous injectionCost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities
Katz JN, Smith SR, Collins JE, Solomon DH, Jordan JM, Hunter DJ, Suter LG, Yelin E, Paltiel AD, Losina E. Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. Osteoarthritis And Cartilage 2015, 24: 409-418. PMID: 26525846, PMCID: PMC4761310, DOI: 10.1016/j.joca.2015.10.006.Peer-Reviewed Original ResearchAgedAged, 80 and overAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalCelecoxibComorbidityCost-Benefit AnalysisDrug CostsDrug Therapy, CombinationFemaleHealth Services ResearchHumansIbuprofenMaleMiddle AgedNaproxenNonprescription DrugsOsteoarthritis, KneePainPain MeasurementProton Pump InhibitorsQuality-Adjusted Life YearsSensitivity and SpecificityTramadolTreatment OutcomeUnited StatesDefining the Value of Future Research to Identify the Preferred Treatment of Meniscal Tear in the Presence of Knee Osteoarthritis
Losina E, Dervan EE, Paltiel AD, Dong Y, Wright RJ, Spindler KP, Mandl LA, Jones MH, Marx RG, Safran-Norton CE, Katz JN. Defining the Value of Future Research to Identify the Preferred Treatment of Meniscal Tear in the Presence of Knee Osteoarthritis. PLOS ONE 2015, 10: e0130256. PMID: 26086246, PMCID: PMC4472814, DOI: 10.1371/journal.pone.0130256.Peer-Reviewed Original ResearchDemographic and clinical features of inclusion body myositis in north America
Paltiel AD, Ingvarsson E, Lee DK, Leff RL, Nowak RJ, Petschke KD, Richards-Shubik S, Zhou A, Shubik M, O'Connor KC. Demographic and clinical features of inclusion body myositis in north America. Muscle & Nerve 2015, 52: 527-533. PMID: 25557419, PMCID: PMC4869122, DOI: 10.1002/mus.24562.Peer-Reviewed Original ResearchConceptsInclusion body myositisBody myositisDaily livingComposite functional indexLarger patient populationWeakness of armsDisease durationClinical featuresInitial diagnosisMean agePatient populationFemale ratioClinical managementClinical trialsOutcome measuresFirst symptomsFunctional indexEarly symptomsNatural historyMean timeSelf-report surveyMyositisPatientsSymptomsDiagnosisLifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty
Losina E, Paltiel AD, Weinstein AM, Yelin E, Hunter DJ, Chen SP, Klara K, Suter LG, Solomon DH, Burbine SA, Walensky RP, Katz JN. Lifetime Medical Costs of Knee Osteoarthritis Management in the United States: Impact of Extending Indications for Total Knee Arthroplasty. Arthritis Care & Research 2015, 67: 203-215. PMID: 25048053, PMCID: PMC4422214, DOI: 10.1002/acr.22412.Peer-Reviewed Original ResearchConceptsTotal knee arthroplastyDirect medical costsOA patientsKnee osteoarthritisMedical costsKnee arthroplastyTKA utilizationEligibility criteriaEffective nonoperative therapiesKellgren/LawrenceKnee osteoarthritis managementKnee OA patientsSymptomatic knee osteoarthritisMulticenter Osteoarthritis StudyLifetime costsUtilization Project dataOsteoarthritis Policy ModelLifetime direct medical costsLifetime medical costsHealth care costsMedicare reimbursement schedulesTotal lifetime costsNonoperative therapySymptomatic osteoarthritisOsteoarthritis management
2014
The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis
Hyle EP, Jani IV, Lehe J, Su AE, Wood R, Quevedo J, Losina E, Bassett IV, Pei PP, Paltiel AD, Resch S, Freedberg KA, Peter T, Walensky RP. The Clinical and Economic Impact of Point-of-Care CD4 Testing in Mozambique and Other Resource-Limited Settings: A Cost-Effectiveness Analysis. PLOS Medicine 2014, 11: e1001725. PMID: 25225800, PMCID: PMC4165752, DOI: 10.1371/journal.pmed.1001725.Peer-Reviewed Original ResearchConceptsCare CD4 testIncremental cost-effectiveness ratioCare CD4 testingPOC CD4CD4 testCD4 testingResource-limited settingsHIV diagnosisHIV testingClinical outcomesAntiretroviral therapy (ART) eligibilityPerson lifetime costsLife expectancyLifetime costsCost-effectiveness ratioResource limited settingsCost-effectiveness analysisSensitivity/specificityImmunological stagingLow sensitivity/specificityCost-effective thresholdLaboratory-based testsSurvivalEditors' SummaryOutcomes
2013
Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness
Yazdanpanah Y, Perelman J, DiLorenzo MA, Alves J, Barros H, Mateus C, Pereira J, Mansinho K, Robine M, Park JE, Ross EL, Losina E, Walensky RP, Noubary F, Freedberg KA, Paltiel AD. Routine HIV Screening in Portugal: Clinical Impact and Cost-Effectiveness. PLOS ONE 2013, 8: e84173. PMID: 24367639, PMCID: PMC3867470, DOI: 10.1371/journal.pone.0084173.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioQuality-adjusted life monthsRoutine HIVHIV test acceptanceRoutine HIV screeningAge 43 yearsCells/μLSecondary HIV transmissionHigh-risk groupHigh-risk populationRoutine screening programQuality-adjusted survivalCost-effectiveness ratioCD4 countHIV screeningClinical outcomesHIV prevalenceHIV transmissionFrequent screeningClinical impactNational HIVScreening programHigh incidenceHIV